Comparison
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 vs 13q12 3 Microdeletion Syndrome C4750951
Clinical comparison between 17 Alpha Hydroxylase 7 20 Lyase Deficiency CN380063 and 13q12 3 Microdeletion Syndrome for differential diagnosis and treatment planning.
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
A rare genetic disorder affecting steroid hormone production. Causes ambiguous genitalia, lack of puberty, and high blood pressure. Requires lifelong hormone replacement therapy.
13q12 3 Microdeletion Syndrome C4750951
A rare genetic condition where a small piece of chromosome 13 is missing. It can cause various developmental and medical concerns. Care is supportive and tailored to the individual's needs.
6 comparison axes
Onset
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
0-18
13q12 3 Microdeletion Syndrome C4750951
0-null
Onset patterns differ
Severity
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
severe
13q12 3 Microdeletion Syndrome C4750951
moderate
Different severity levels
Chronic
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
Chronic
13q12 3 Microdeletion Syndrome C4750951
Chronic
Differing course
Communicable
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
No
13q12 3 Microdeletion Syndrome C4750951
No
Different transmission
Body System
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
13q12 3 Microdeletion Syndrome C4750951
congenital
Same/different system
Category
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
13q12 3 Microdeletion Syndrome C4750951
genetic
Different category
Bottom line
17-alpha-hydroxylase-7-20-lyase-deficiency-CN380063 and 13q12-3-microdeletion-syndrome-C4750951 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | 13q12 3 Microdeletion Syndrome C4750951 | Discriminating power |
|---|---|---|---|
| Blood pressure | Hypertension is a recognized feature, often with suppressed renin-aldosterone physiology. | Hypertension is not a defining feature in the supplied description. | High |
| Puberty and genital development | Absent or incomplete puberty and ambiguous genitalia may occur from impaired sex-steroid production. | Genital or pubertal findings are not established by the supplied source. | High |
| Development | Primary developmental disability is not the defining presentation. | Developmental concerns may occur, with variable medical features. | Moderate |
When to favor each condition
Choose 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 when
Hypertension with delayed puberty or atypical genital development
This pattern points toward disordered adrenal and gonadal steroid synthesis.
High
Abnormal steroid profile suggesting CYP17A1-related deficiency
Endocrine testing, interpreted by a specialist, supports this diagnosis over a chromosomal syndrome.
Moderate
Need for lifelong sex-steroid and glucocorticoid replacement
Hormone replacement is characteristic management, with doses individualized.
High
Choose 13q12 3 Microdeletion Syndrome C4750951 when
Developmental concerns with a detected 13q12.3 deletion
A chromosomal microarray or equivalent result directly supports the microdeletion diagnosis.
High
Multisystem congenital features without a steroid-deficiency pattern
Supportive, individualized care fits the described chromosomal condition.
Moderate
Normal targeted endocrine evaluation
Absence of the expected steroid abnormality makes the enzyme deficiency less likely.
Moderate
How key tests differ
| Test | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | 13q12 3 Microdeletion Syndrome C4750951 | Interpretation |
|---|---|---|---|
| Steroid hormone profile | Pattern consistent with impaired 17-hydroxylase/17,20-lyase activity; exact cutoffs vary. | No characteristic steroid abnormality is established. | An abnormal profile supports, but does not alone prove, the enzyme deficiency. |
| Genetic testing | Biallelic CYP17A1 variants may confirm the diagnosis. | Chromosomal microarray may show a 13q12.3 microdeletion. | The genetic method and result distinguish the conditions. |
| Blood pressure and electrolytes | Hypertension may occur; potassium findings are variable and not definitive here. | No specific blood-pressure or electrolyte pattern is supplied. | Results need clinical correlation and should not be treated as diagnostic cutoffs. |
Prognosis comparison
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
- Outcome
- Chronic condition; outcomes depend on hormone management and blood-pressure control. Mortality is not established here.
- Factors
- Diagnosis timing, adherence, blood pressure, and puberty management.
13q12 3 Microdeletion Syndrome C4750951
- Outcome
- Chronic condition with variable developmental and medical impact; prognosis is not uniformly established.
- Factors
- Deletion effects, associated anomalies, developmental support, and comorbidities.
Time frame: Lifelong for both; onset is typically childhood, with variable recognition.
Genetic confirmation, specialist care, and individual complications determine course.
Complications comparison
| Complication | Presentation |
|---|---|
| Hypertension-related harm | Long-standing hypertension may affect cardiovascular and renal health. Not established as a characteristic complication. Monitoring is individualized; no outcome rate is supplied. |
| Pubertal and fertility effects | Impaired sex-steroid production may affect puberty, sexual development, and fertility. Effects are not established from the supplied description. Endocrine and reproductive counseling may be appropriate. |
| Developmental and medical complexity | Not the primary described burden. Variable developmental and medical concerns may require coordinated support. Severity and needs differ among individuals. |
Patient education highlights
- HighDifferent causes
One condition disrupts steroid production; the other involves missing chromosomal material. Neither is communicable.
- HighSpecialist follow-up
Endocrine care is central for the enzyme deficiency, while the microdeletion needs tailored developmental and medical support.
- MediumAvoid self-adjustment
Do not change hormone therapy or interpret test results without a clinician.